Company
Company description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Quick Presentation Filters
Related Companies

Filter

      Loading ...

      Loading ...

      Loading ...

Filter

      Loading ...

      Loading ...

      Loading ...

Presentations (10)
Investor Presentation
April 2024
42 slides
Investor Presentation
February 2024
42 slides
Investor Presentation
January 2024
42 slides
Investor Presentation
January 2024
41 slides
Investor Presentation
November 2023
52 slides
Investor Presentation
October 2023
52 slides
Investor Presentation
August 2023
39 slides
Investor Presentation
May 2023
39 slides
Investor Presentation
October 2022
31 slides
IPO
July 2021
40 slides
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io